Atopic dermatitis causes chronic itching and discomfort in millions of dogs. Modern treatments including biologics provide dramatically improved control and quality of life.
Canine atopic dermatitis causes chronic welfare harm through persistent pruritus that disrupts sleep, normal behavior, and social interaction. Affected dogs may scratch, rub, chew, and lick constantly, causing secondary skin damage, hot spots, and ear infections that compound the primary welfare burden. The chronic, relapsing nature of the condition requires sustained management commitment and creates ongoing owner concern. Modern biologic therapies including lokivetmab and the JAK inhibitor oclacitinib have transformed management by providing rapid, sustained itch relief with profiles that allow long-term use in most affected dogs. The welfare improvement from effective itch control — dogs return to normal sleep, activity, and social behavior — is immediate and dramatic. Allergen-specific immunotherapy offers the prospect of long-term remission in well-selected patients.